WideMed Ltd. (WDMD) Receives FDA 510(k) Clearance to Market its
Morpheus Ox for Home Sleep Diagnosis   9/12/2011 8:00:34 AM
HERZLIYA, Israel--(BUSINESS WIRE)-- WideMed (TASE:WDMD.ta -
News), a leading company engaged in the research, development
and sale of innovative products for the growing bio-medical
signal diagnostics and treatment market, announced today that
the U.S. Food and Drug Administration has granted its home sleep
monitoring device, Morpheus Ox, clearance to market in the
United States for cardiac patient population.  Morpheus® Ox is
WideMed’s portable home sleep diagnostic and monitoring
solution. Easy to use, watch-size device enables to perform a
sleep test in the comfort of the patient own bedroom.  The
Morpheus Ox measures photoplethysmography (PPG) and blood
saturation, signals from a standard oximeter device. By
utilizing WideMed’s automatic sleep scoring software, Morpheus
Ox produces an accurate and reliable sleep study diagnosis,
including Sleep/Wake, Apnea Hypopnea Index (AHI) and C